Rational Pharmacotherapy in Cardiology

Advanced search


Full Text:


Background. Digoxin takes important place in the management of patients with paroxysmal or persistent atrial fibrillation (AF). Monitoring of serum digoxin concentration (SDC) seems to be perspective way to improve the safety and efficacy of treatment. At the same time, there are no generally accepted reference ranges for SDC, especially in terms of the onset of therapy.

Aim. To evaluate the potential contribution of SDC monitoring in the context of efficacy of AF treatment with the use of digoxin in elderly patients.

Material and methods. A retrospective analysis of treatment of patients with recent-onset (n=91) or permanent (n=58) AF was performed. In all cases, the strategy of heart rate (HR) control was realized, including treatment with digoxin in 104 cases. SDC was measured twice during the digitalization: 20 hours after the first digoxin dose, and at the endpoint (time of sinus rhythm spontaneous restoration or, if the rhythm not restored, on day 7 of AF persistence).

Results. The influence of digoxin on HR was dose-dependent since the 1st week of therapy, and the SDC dynamics was strictly associated with change in HR (r=-0.66, p<0.001). There was a negative correlation between the probability of the sinus rhythm restoration due to digoxin therapy and the SDC: its probability in high SDC was significantly lower compared to other approaches to the HR control (0% vs 76% in beta-blocker monotherapy; and vs 100% in therapy with beta-blocker + lower-SDC, p=0.036). In patients with persisted AF and low SDC, the digoxin was withdrawn more often due to lack of clinical efficiency.

Conclusions. The SDC monitoring at the 1st week of digitalization could be used to improve the efficacy of therapy and to minimize the risks of spontaneous rhythm restoration, if not desired, and to reveal the disproportion between its high dose and low efficacy. The role of this diagnostic tool seems to be limited to safety control and negative predictive value for efficacy (the lower concentration, the higher risk of inefficiency), whereas its positive predictive value in terms of efficacy seems contradictory. The obtained data could be used for decision-making for recommendation of longterm digoxin usage if its contribution into HR control is doubtful. 

About the Authors

S. F. Zadvorev
St. Petersburg City Hospital №2
Russian Federation

MD, Cardiologist,

Uchebniy per. 5, St. Petersburg, 194354

A. A. Yakovlev
St. Petersburg City Hospital №2; Saint Petersburg State University
Russian Federation

MD, PhD, Нead of Cardiology Department, Uchebniy per. 5, St. Petersburg, 194354;

Assistant, Chair of Hospital Therapy, Faculty of Medicine, Universitetskaya nab. 7-9, St. Petersburg, 199034

A. S. Pushkin
St. Petersburg City Hospital №2
Russian Federation

MD, PhD, Doctor of Clinical Laboratory Diagnostics,

Uchebniy per. 5, St. Petersburg, 194354

S. A. Rukavishnikova
St. Petersburg City Hospital №2
Russian Federation

PhD (Biology), Head of Clinical Diagnostic Laboratory,

Uchebniy per. 5, St. Petersburg, 194354

A. E. Filippov
Saint Petersburg State University; International Medical Center “SOGAZ”
Russian Federation

MD, PhD, Professor, Chair of Hospital Therapy, Faculty of Medicine, Universitetskaya nab. 7-9, St. Petersburg, 199034;

Cardiologist, Malaya Konyushennaya ul. 8, St. Petersburg, 191186

A. G. Obrezan
Saint Petersburg State University; International Medical Center “SOGAZ”
Russian Federation

MD, PhD, Professor, Chair of Hospital Therapy, Faculty of Medicine, Universitetskaya nab. 7-9, St. Petersburg, 199034;

Head Physician, Malaya Konyushennaya ul. 8, St. Petersburg, 191186


1. Strelnikov A.A., Obrezan A.G., Shaydakov E.V. Screening and prophylaxis for internal diseases. Saint Petersburg: SpetsLit: 2012. (In Russ.) [Стрельников А.А., Обрезан А.Г., Шайдаков Е.В. Скрининг и профилактика актуальных заболеваний. СПб.: СпецЛит: 2012].

2. Ziff O.J., Kotecha D. Digoxin: the good and the bad. Trends in Cardiovascular Medicine. 2016;26(7):585-95. doi: 10.1016/j.tcm.2016.03.011.

3. Kirchhof P., Benussi S., Kotecha D., et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J. 2016;37(38):2893-962. doi: 10.1093/eurheartj/ehw210.

4. Revishvili A.S., Shlyakhto Y.V., Sulimov V.A. et al. Diagnosis and treatment of atrial fibrillation. Clinical guidelines (2017). [cited 2018 Jan 25]. Available from: (In Russ.) [Ревишвили А.Ш., Шляхто Е.В., Сулимов В.А. и др. Диагностика и лечение фибрилляции предсердий. Клинические рекомендации (2017). [цитировано 25.01.2018]. Доступно на:].

5. The Digitalis in acute atrial fibrillation (DAAF) Trial Group. Intravenous digoxin in acute atrial fibrillation. Results of a randomized, placebo-controlled multicenter trial in 239 patients. Eur Heart J. 1997;18:649-54.

6. Rawles J.M., Metcalfe M.J., Jennings K. Time of occurrence, duration, and ventricular rate of paroxysmal atrial fibrillation: the effect of digoxin. Br Heart J. 1990;63:225-7. doi: 10.1136/hrt.63.4.225.

7. Murgatroyd F.D, Gibson S.M., Baiyan X., et al. Double-blind placebo-controlled trial of digoxin in symptomatic paroxysmal atrial fibrillation. Circulation. 1999;99:2765-70. Doi: 10.1161/01.CIR. 99.21.2765.

8. Bobrov L.L., Gaivoronskaya V.V., Kulikov A.N., et al. Clinical pharmacology and pharmacotherapy of internal diseases. St. Petersburg: VMedA; 2000. (In Russ.) [Бобров Л.Л., Гайворонская В.В., Куликов А.Н., и др. Клиническая фармакология и фармакотерапия внутренних болезней. СПб.: ВМедА; 2000].

9. Akimov A.G., Obrezan A.G. Management of heart failure. St. Petersburg: InformMed. 2010. (In Russ.) [Акимов А.Г., Обрезан А.Г. Лечение хронической сердечной недостаточности. СПб: ИнформМед; 2010].

10. Krysiuk O.B., Obrezan O.B., Ponomarenko G.N. Problems of personified medicine in internal diseases. Vestnik SPbGU. 2006;1:16-22. (In Russ.) [Крысюк О.Б., Обрезан А.Г., Пономаренко Г.Н. Проблемы персонифицированной медицины в клинике внутренних болезней. Вестник Санкт-Петербургского Университета. 2006;1:16-22].

11. Ahmed A., Pitt B., Rahimtoola S.H. et al. Effects of digoxin at low serum concentrations on mortality and hospitalization in heart failure: A propensity-matched study of the DIG trial. Int J Cardiol. 2008;123:138-46. doi: 10.1016/j.ijcard.2006.12.001.

12. Eichhorn E.J., Gheorghiade M. Digoxin. Prog Cardiovasc Dis. 2002;44(4):251-66. doi: 10.1053/pcad.2002.31591.

13. Ouyang A.J., Lv Y.N., Zhong H.L., et al. Meta-analysis of digoxin use and risk of mortality in patients with atrial fibrillation. Am J Cardiol. 2015;115:901-6. doi: 10.1016/j.amjcard.2015.01.013.

14. Kotecha D., Kirchhof P. Rate and rhythm control have comparable effects on mortality and stroke in atrial fibrillation but better data are needed. Evid Based Med. 2014;19:222-3. doi: 10.1136/ebmed-2014-110062.

15. Obrezan A.G., Skorodumova E.A., Kostenko V.A. et al. Influence of chronic kidney disease on inhospital period of myocardial infarction. Vestnik SPbGU. 2014;4:50-5. (In Russ.) [Обрезан А.Г., Скородумова Е.А., Костенко В.А. и др. Влияние хронической болезни почек на течение инфаркта миокарда в госпитальном периоде. Вестник Санкт-Петербургского Университета. 2014;4:50-5].

For citation:

Zadvorev S.F., Yakovlev A.A., Pushkin A.S., Rukavishnikova S.A., Filippov A.E., Obrezan A.G. OPTIMIZATION OF THE HEART RATE CONTROL IN ATRIAL FIBRILLATION BY MONITORING OF THE DIGOXIN CONCENTRATION IN ELDERLY PATIENTS. Rational Pharmacotherapy in Cardiology. 2018;14(3):330-336. (In Russ.)

Views: 126

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.

ISSN 1819-6446 (Print)
ISSN 2225-3653 (Online)